期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.666233
关键词
imaging mass cytometry; tumor immune microenvironment; biomarkers; immune therapies; panel design
类别
资金
- Centre National de la Recherche Scientifique
- Institut national de la sante et de la recherche medicale
- Universite Cote d'Azur
- Canceropole PACA
- Region Provence-Alpes-Cote d'Azur
- Fondation d'entreprise SILAB Jean PAUFIQUE
- Fondation d'Entreprise Bristol-Myers Squibb pour la Recherche en Immuno-Oncologie
- Fondation ARC pour la recherche sur le Cancer
- Ligue Nationale contre le Cancer
- Fondation de l'Avenir
- French Government (National Research Agency, ANR) through the Investments for the Future program LABEX SIGNALIFE [ANR-11-LABX-0028]
- French Government (National Research Agency, ANR) through the Investments for the Future program IDEX UCAJedi [ANR-15-IDEX-01]
The IMC panel with 39 antibodies designed for staining human tumor sections provides a powerful tool for studying tumor immune microenvironment, revealing interactions between immune cells and structural components such as tumor cells.
The integrative analysis of tumor immune microenvironment (TiME) components, their interactions and their microanatomical distribution is mandatory to better understand tumor progression. Imaging Mass Cytometry (IMC) is a high dimensional tissue imaging system which allows the comprehensive and multiparametric in situ exploration of tumor microenvironments at a single cell level. We describe here the design of a 39-antibody IMC panel for the staining of formalin-fixed paraffin-embedded human tumor sections. We also provide an optimized staining procedure and details of the experimental workflow. This panel deciphers the nature of immune cells, their functions and their interactions with tumor cells and cancer-associated fibroblasts as well as with other TiME structural components known to be associated with tumor progression like nerve fibers and tumor extracellular matrix proteins. This panel represents a valuable innovative and powerful tool for fundamental and clinical studies that could be used for the identification of prognostic biomarkers and mechanisms of resistance to current immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据